Picture of CorMedix logo

CRMD CorMedix Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+28.07%
3m+16.31%
6m+40.07%
1yr-7.6%
Volume Change (%)
10d/3m-32.99%
Price vs... (%)
52w High-48.16%
50d MA+28.67%
200d MA+5.48%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.05
Price to Tang. Book3.05
Price to Free Cashflown/a
Price to Sales1,864.44
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-52.64%
Return on Equity-46.61%
Operating Margin-32585.67%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of CorMedix EPS forecast chart

Profile Summary

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
July 28th, 2006
Public Since
March 25th, 2010
No. of Shareholders
272
No. of Employees
29
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
41,282,134

CRMD Share Price Performance

Upcoming Events for CRMD

CorMedix Inc Annual Shareholders Meeting

Q4 2022 CorMedix Inc Earnings Release

Q1 2023 CorMedix Inc Earnings Release

Similar to CRMD

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aptorum logo

Aptorum

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email